Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07333027

Lonely in Depression

The goal of this prospective study is to better understand the link between loneliness and depression in the inpatient psychiatric treatment of depression. It aims to answer:

Do lonely and not lonely persons benefit the same way from inpatient depression treatment? Is loneliness a clinical relevant factor in inpatient treatment of depression? What are the underlying biopsychosocial mechanisms?

Participants will be asked to do some

* self-report questionnaires * clinical interview * biosampling (blood, saliva, stool) at three main measurement timepoints (1. begin of inpatient treatment, 2. day of discharge, 3. three months after discharge).

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Bezirkskliniken Mittelfranken, Clinic for Psychiatry, Addiction, Psychotherapie and Psychosomatic Medicine, Erlangen, Bavaria, Germany

Loading trial locations.

About this study

Loneliness and depression are widespread and severely debilitating health conditions. Notably, loneliness and depression are closely intertwined, with individuals suffering from depression being particularly vulnerable to loneliness. However, little is known regarding the clinical significance of loneliness in the treatment of depression and the biopsychosocial mechanisms underlying this association.

To examine the clinical relevance of the interplay between loneliness and depression, a prospective, noninterventional longitudinal design will be adopted. The study will be performed at the University Hospital and the community hospital in Erlangen, Germany. Every patient admitted to the hospital with depressive symptoms is eligible for screening according to the inclusion and exclusion criteria. Three main measurement points (T0, T1, and T2) and brief interim measurements conducted at two-week intervals (t0.1 to t0.X and t1.1-t1.6) will be utilized. After screening and clinical interviews, participants will complete the baseline measurements (T0). Thereafter, each participant will adhere to an individual period corresponding to the duration of that specific patient's inpatient stay at the clinic until the second measurement is obtained (T1). Follow-up will occur three months after T1.

Given that the effect sizes of the interaction between loneliness and depression in a clinical population are currently unknown, the sample size for this study was determined based on considerations of practicability and the population generalizability of the obtained results, as well as statistical plausibility.

To ensure the external validity of the results, it is important that both severely lonely depressive patients and less lonely depressive patients, as well as different disease trajectories and patient characteristics (e.g., age, sex, and number of comorbidities), can be identified. A sample size of approximately 200 participants is expected to ensure sufficient heterogeneity. This sample size is practically feasible due to the fact that, even when considering an inclusion rate of 50% and a dropout rate of 30% for the primary diagnosis of depression at the University Hospital and the community hospital in Erlangen, the recruitment potential clearly exceeds the target number of cases within an estimated period of two years.

Without the knowledge of which measured level of loneliness at baseline represents a strong level of loneliness and which measured level represents a weak level of loneliness in a depressed patient population, a median split of loneliness at baseline will be performed to calculate the statistical significance of the interaction between loneliness and depression in the inpatient and follow-up course (T0, T1, and T2). To detect a significant interaction effect of a mixed analysis of variance (ANOVA), when considering an α error of 0.05, a power of 0.9 (1-β error probability) and a correlation value among repeated measures of 0.5 for the groups defined as highly lonely and slightly lonely groups, the number of cases was calculated by using G*Power Version 3.1.9.7. Assuming a small effect size (f= 0.10), the desired sample size would be determined at n= 214 individuals; moreover, assuming a medium effect size (f= 0.25), the sample size would be n= 36 individuals. This indicates that there is statistical plausibility for detecting interaction effects between loneliness and depression with the target number of cases.

Eligibility screening and clinical diagnostic screening, along with interviews, are conducted by study physicians. Depression is assessed during a clinical interview (MADRS) by the patient's treatment team, which also determines when the patient will be discharged from the hospital. All of the self-report assessments are collected by the patients themselves by using the REDCap online survey application. Biosampling will be exclusively performed among participants recruited at the University Hospital to ensure methodologically consistent and rapid processing. Routine clinical data are primarily extracted from clinical documentation systems and consolidated prior to analysis (similar to other data sources).

Given that the study design does not permit definitive causal conclusions to be determined regarding the direction of effects, the findings are expected to provide valuable insights and relevant implications. In particular, the following insights can be obtained: (1) a report on whether more or less lonely patients receive equal benefits from inpatient multimodal depression treatment; (2) insights into changes in loneliness during and after depression treatment; (3) important findings regarding the shared and nonshared biopsychosocial mechanisms underlying loneliness and depression; and (4) the effects of loneliness and depression with respect to secondary outcomes, including quality of life and suicidality.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • primary diagnosis of depression according to ICD-10 (F32 or F33), as diagnosed by a physician or clinical psychologist in conjunction with the M.I.N.I. Mini-International Neuropsychiatric Interview diagnostic tools
  • inpatient elective or emergency admission to one of the two psychiatric clinics; - age over 18 years
  • sufficient understanding of spoken and written German
  • informed voluntary consent

Exclusion criteria

  • a current lack of capacity to provide consent (e.g., pronounced psychotic symptoms, stuporous depressive syndrome, and thought constriction to suicidality)
  • previous participation in the study
  • pregnancy or breastfeeding
  • inpatient stay of less than 7 days, even if the patients initially met the inclusion criteria.

Treatment and study plan

Primary outcomes

  1. Depression (symptom severity)

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    Montgomery-Åsberg Depression Rating Scale (MADRS) (10 Items, each item rated 0-6 points, minimum 0 points, maximum 60 points, higher scores indicate greater severity of depressive symptoms)

  2. Loneliness

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    3 Item UCLA Loneliness Scale (3-Item UCLA) (3 items, each item rated 1-3 points, minimum 3 points, maximum 9 points, higher scores indicate greater loneliness)

  3. Depression

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    Patient Health Questionnaire, 9-Item Depression Scale (PHQ-9) (9 Items, each item rated 0-4 points, minimum 0 points, maximum 27 points, higher scores indicate greater severity of depression)

  4. Loneliness

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    6-Item short scales for Loneliness, De Jong Gierveld Loneliness Scale (6-Item DJGLS) (6 Items, each item rated 1-3 points, before the total score is calculated, the items are dichotomized, thus resulting in a sum score ranging from 0 to 6, wherein scores of 0-1 indicate no loneliness, 2-4 indicate moderate loneliness, and 5-6 indicate severe loneliness)

Secondary outcomes

  1. Social Support

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    Fragebogen zur Sozialen Unterstützung (F-SoZ-U 14) (14 Item shortend form, each item rated 0-4 points, minimum 0 points, maximum 56 points, higher total scores indicating higher levels of perceived social support)

  2. Inpatient treatment duration

    Time frame: Baseline/T0 (day 1 of inpatient stay) to T1 (end of inpatient stay, normally 7 up to 50 weeks).

    in days

  3. Quality of life in self-report

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    World Health Organization-Five Well-Being Index (WHO-5) (5 Items, each item rated 0-5 points, minimum 0 points, maximum 25 points, the total score (0-25) is transformed to a scale ranging from 0 to 100, with scores ≤50 indicating diminished well-being and higher scores representing higher well-beeing)

  4. Social Network measure (newly designed for this study)

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    As there is no culture and language adapted version of a social network indice available an adapted and German-translated version is used to capture participants' social interaction partners during the prior two weeks. The questionnaire was newly developed, with item content informed by existing validated scales (Cohen Social Network Index (SNI), Lubben Social Network Scale (LSNS), Berkman - Social Network/Integration).

    Via the use of a yes/no response format, participants indicated whether they had personal or telephone contact with each of the following: (1) spouse or partner, (2) own children, (3) parents or parent-like figures, (4) other relatives (e.g., siblings, uncles, or aunts), (5) friends, (6) neighbors, (7) colleagues, (8) people known through voluntary activities, (9) in-laws (parents, sons, or daughters-in-law), and (10) members of their social group (e.g., community, congregation, sports, or music clubs).

    Higher total scores indicate greater social connectedness.

  5. General health status

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    Short Form 12 Health Survey (SF-12) (12 Items, Items rated 0-1, 1-3 and 1-5 and 1-6 scores represent eight dimensions of physical and mental well-beeing with two composite scores, items are recodet, z-transformed and normed, higher values indicate better health)

  6. Social Anxiety

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    Social Phobia Inventory (SPIN) (17 Items, each item rated 0-4 points, minimum 0 points, maximum 68 points, higher scores indicate greater severity of social anxiety, three subscales are available (fear 6 items, avoidance 7 items, physiological distress 4 items))

  7. Somatic Symptom Burden

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    13-Item Somatic Symptom Severity Scale of the Patient Health Questionnaire (PHQ-13) (13 Items, each item rated 0-2 points, minimum 0 points, maximum 34 points, higher values indicating more somatic symptoms)

Other outcomes

  1. Blood markers (metabolic, LDL)

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    LDL cholesterin [mg/dl or mmol/l], higher values (> 100 mg/dl or > 2.6 mmol/l) represent unfavorable metabolic risk

  2. Blood markers (metabolic, HDL)

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    HDL cholesterin [mg/dl or mmol/l), < 40 mg/dl men and < 50 mg/dl women represents unfavorable metabolic risk, ≥ 40 mg/dl men ≥ 50 mg/dl women acceptable, ≥ 60 mg/dl protective

  3. Blood markers (metabolic, HbA1c)

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    HbA1c [%], higher values (> 5.7%) represent unfavorable metabolic risk

  4. Blood markers (Sphingolipid metabolism)

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    Sphingolipid metabolism enzyme activity of secretory acid sphingomyelinase (S-ASM) [nmol/mL/h/µL], higher leveles represent more inflammation/apoptosis enzyme activity of neutral acid sphingomyelinase (N-ASM) [nmol/mL/h/µL], higher levels represent cellular stress/apotosis Ceramide [nmol/L], higher levels represent more inflammation/apoptosis

  5. Blood markers (neutrotrophic factor, BDNF)

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    brain-derived neurotrophic factor [ng/mL], higher levels represent more neuroplasticity

  6. Blood markers (hormonal)

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    Cortisol [µg/dL or nmol/L] and timepoint of blood test higher levels represent more stress response

  7. Blood markers (immunological markers)

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    C-reactive protein (CRP) [mg/L], higher levels show systemic inflammation

  8. Saliva marker (cortisol)

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    saliva cortisol (awakening and before bedtime), higher levels represent more stress response

  9. Saliva marker (α-amylase)

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    saliva α-amylase activity [U/ml] (awakening and before bedtime), higher levels represent more stress response

  10. Stool markers

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    alpha-diversity

  11. Suicidality (clinician rated)

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    measures in clinical interview (Montgomery-Åsberg Depression Rating Scale (MADRS)) (Item No. 10 out of 10 items, rated 0-6, higher values represent more suicidality)

  12. Suicidality (self-report)

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    9-Item Patient Health Questionnaire (PHQ-9) (Item No. 9 out of 9, rated 0-3 with higher scores indicating more suicidality)

  13. Response (depression)

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7) to T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks).

    ≥ 50% reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) score from T0 to T1 (10 Items, each item rated 0-6 points, minimum 0 points, maximum 60 points, higher scores indicate greater severity of depressive symptoms)

  14. Relapse (depression)

    Time frame: T1 (end of inpatient stay/discharge from clinic ± 7 d) to Follow-Up/T2 (three months after clinical discharge ± 7 d).

    ≥ 10 points more from T1 to T2 in Montgomery-Åsberg Depression Rating Scale (MADRS) score or ≥ 22 points at T2 (10 Items, each item rated 0-6 points, minimum 0 points, maximum 60 points, higher scores indicate greater severity of depressive symptoms)

  15. Antidepressant medication

    Time frame: Baseline/T0 (normally day 1 of inpatient stay and maximum of day 2), T1 (end of inpatient stay, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    consideration of these classes of antidepressant drugs if these are given in a dosage that is effective as an antidepressant (e.g. for Mirtazapin not 7.5 mg, starting from 15 mg): SSRI/SNRI/NaSSA(Mirtazapin)/NDRI (Buproprion)/TZA/MAO-I/SARI (Trazodon)Agomelatin/other with classes of augmentation strategy: Lithium/antipsychotics/second antidepressant/other augmentation strategy sorted as: antidepressant monotherapy/antidepressant augmented therapy/other and change in therapy stategy (1. no; 2. yes drug substance (2.1) added/ (2.2) changed/ (2.3) removed; 3. yes dosage of antidepressant changed (3.1) increased/(3.2) decreased; 4. augmentation strategy changed)

  16. trait vs. state loneliness

    Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

    Given the absence of an established measure capable of differentiating between enduring (trait) and situational (state) loneliness, this aspect is captured by using a newly developed single item: 'In looking back upon my life, I would say that I have felt …'. Participants respond to this item on a four-point scale (1= mostly lonely throughout my life, 2= lonely from time to time, 3= only lonely at present, and 4= never lonely). Responses of 1 are intended to represent trait loneliness; options 2 and 3 represent state loneliness; and option 4 indicates no loneliness.

  17. number of therapies participated

    Time frame: Baseline/T0 (normally day 1 of inpatient stay and maximum of day 2) to T1 (end of inpatient stay, normally 7 days up to 50 weeks).

    frequency per week of psychotherapy, group interventions and other

Study contacts

Contact information is provided by the study sponsor or research team.

Franca Fries, Dr. med.

CONTACT

[email protected]

004991317530

Franziska Sonnauer, Dr. med., M.Sc.

CONTACT

[email protected]

00499131-8534597

Sponsors and collaborators

Lead sponsor

Friedrich-Alexander-Universität Erlangen-Nürnberg

Other

Collaborators

  • Bezirkskliniken Mittelfranken, Clinic for Psychiatry, Addiction, Psychotherapie and Psychosomatic Medicine, Am Europakanal, Germany

Registry information

Official study title

Effects of Loneliness in the Treatment of Depression

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jan 12, 2026
Registry last updated
Jun 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.